GlassScriptPhysician profile
Rajiv Amesur
NPI 1538422183
$8,708.86
in general payments reported to CMS, 2019-2025
13 companies · $4,015 in 2025
The $4,015 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $135 · 2023: $112 · 2024: $4,322 · 2025: $4,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,577 · Travel and Lodging: $1,867 · Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,576.99 |
| Travel and Lodging | $1,867.05 |
| Food and Beverage | $1,005.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,322.26 | 2024-2025 | |
| Olympus Corporation of The Americas | $655.92 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $193.73 | 2022-2023 | Opsumit, Uptravi |
| Penumbra, INC. | $137.00 | 2024 | Indigo System |
| Veran Medical Technologies, INC. | $107.62 | 2021 | |
| Olympus America INC. | $61.00 | 2025 | |
| Fujifilm Healthcare Americas Corporation | $59.43 | 2025 | |
| Verona Pharma, INC. | $48.89 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $42.61 | 2023-2025 | Trelegy Ellipta |
| Tactile Systems Technology INC | $24.93 | 2025 | Flexitouch Plus, Nimbl |
| Astrazeneca Pharmaceuticals LP | $20.10 | 2023 | Breztri |
| Baxter Healthcare | $18.34 | 2022 | |
| Advanced Respiratory, INC | $17.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Amesur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.